NCT04824937View on ClinicalTrials.gov

Telaglenastat + Talazoparib In Prostate Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Telaglenastat

Capsule, taken by mouth

DRUG

Talazoparib

Capsule, taken by mouth

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Calithera Biosciences, Inc

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

Prostate Cancer Foundation

OTHER

lead

Massachusetts General Hospital

OTHER